Updates

Every registered medication has an information insert in its package. This patient information leaflet (PIL) provides data on the product, which includes clinical pharmacology, recommended dose, mode of administration, how supplied, and a large section contains warnings and contraindications, adverse reactions, and precautions. With easy access of patients to information on drugs they use, mainly… Read More

An IMS symposium was held at the recent Colegio Mexicano de Especialistas en Ginecología y Obstetricia held in Mexico City on 13th March, and hosted by the COMEGO President, Cuauhtémoc Celis González. The symposium focused on the Fundamentals of Menopausal Medicine. This 90-minute plenary symposium was uniquely held in English and Spanish, with two Board… Read More

Many of us were exposed to the news in mid-February that a meta-analysis by Beral and colleagues [1] published in [i]The Lancet[/i] concluded that even a short-term use (< 5 years) of postmenopausal hormone therapy (HT) is associated with increased risk for ovarian cancer. Analyses used individual participant datasets from 52 epidemiological studies. The principal… Read More

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. The Lancet. Published online, 12 February 2015 - Please find attached analysis of the recent published paper in The Lancet which discusses HRT and ovarian cancer risk.This includes: A statement from IMS President, Dr Rodney Baber outlining the IMS position. A… Read More

In the recent [i]BoneKEy Reports[/i] review [1], it was noted that combinations of anabolic and antiresorptive agents have potential to improve bone density and bone strength more than either agent as monotherapy. Small clinical trials have been performed evaluating combinations of parathyroid hormone (PTH) – PTH 1-34 (teriparatide) or PTH 1-84 – with a variety… Read More

Vasomotor symptoms (VMS) are common, but whether VMS are associated with fracture incidence or bone mineral density (BMD) levels is unknown. The following data are derived from the Women's Health Initiative Clinical Trial participants ([i]n[/i] = 23,573) aged 50–79 years not using menopausal hormone therapy, and 4867 participants of the BMD sub-study [1]. This was… Read More

Estrogen receptor beta (ERβ) was described already some 15 years ago, but received much less attention than ERα. Like ERα, ERβ is a member of the nuclear receptor superfamily of proteins that functions as a ligand-mediated transcription factor. The DNA binding domains of ERα and ERβ share 96% homology at the amino acid level; however,… Read More

IMS would like to offer sincere congratulations to Professor Susan Davis who has been awarded a 2015 Laureate for International Excellence in Endocrinology Award by The Endocrine Society.Please follow the link for further news https://www.endocrine.org/news-room/current-press-releases/endocrine-society-announces-2015-laureate-award-winners.… Read More

Blood levels of dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS) and androgens, such as testosterone, fall with age. Over the last two decades, there have been many clinical trials performed replacing these sex hormones, hoping to improve symptoms such as general well-being, energy, and sex drive. DHEAS is the most abundant steroid in serum; however, no receptor… Read More

A new article reviews the effects of age-related hormone decline on the aging process and age-related diseases such as sarcopenia and falls, osteoporosis, cognitive decline, mood disorders, cardiovascular health and sexual activity [1]. Information on the efficiency and safety of hormone replacement protocols in aging patients is provided as well. Anti-aging therapies are a huge… Read More